Shopping Cart
Remove All
Your shopping cart is currently empty
TLR8 agonist 10
Copy Product Info
🥰Excellent
Synonyms:
Catalog No. T218576 Copy Product Info
🥰Excellent
TLR8 agonist10 is a specific TLR8 agonist with an EC50 of 0.019 μM in humans. It activates TLR8-mediated signaling pathways and functions as a latency-reversing agent capable of reactivating latent HIV-1 reservoirs. Additionally, TLR8 agonist10 can stimulate innate cytotoxic natural killer cells to target HIV-infected CD4+ T cells. This compound is useful for research related to HIV-1 infection.
TLR8 agonist 10
Cas No. 2796210-93-8
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | 10-14 weeks | 10-14 weeks | |
| 50 mg | Inquiry | 10-14 weeks | 10-14 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | TLR8 agonist10 is a specific TLR8 agonist with an EC50 of 0.019 μM in humans. It activates TLR8-mediated signaling pathways and functions as a latency-reversing agent capable of reactivating latent HIV-1 reservoirs. Additionally, TLR8 agonist10 can stimulate innate cytotoxic natural killer cells to target HIV-infected CD4+ T cells. This compound is useful for research related to HIV-1 infection. |
| Targets & IC50 | TLR8 (Human):0.019 μM |
| In vitro | TLR8 agonist 10 (Compound 23A) at concentrations of 0-10 μM can effectively activate latent HIV-1 in U1 cells in vitro without significant cytotoxicity. Additionally, TLR8 agonist 10 (0-10 μM) can indirectly activate latent HIV-1 in ACH-2 cells through cytokine signaling produced by treated human PBMC, also showing no significant cytotoxicity to ACH-2 cells. Furthermore, TLR8 agonist 10 (0-10 μM) potently activates latent HIV-1 in OM10.1 cells in a concentration-dependent manner with negligible cytotoxicity. |
| In vivo | The compound, TLR8 agonist 10 (1-5 mg/kg; IV injection, gavage; single dose), demonstrates favorable pharmacokinetic properties in male SD rats, characterized by a long half-life and low clearance. Additionally, at a gavage dose of 5 mg/kg, it achieves an oral bioavailability of 35%. |
| Molecular Weight | 326.48 |
| Formula | C20H30N4 |
| Cas No. | 2796210-93-8 |
| Smiles | N=1C(N)=C(C=C(C1C)CC2=CC=C(C=C2)CN(C)C)NCCCC |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: TLR8 agonist 10 in vivo | TLR8 agonist 10 in vitro | TLR8 agonist 10 formula | TLR8 agonist 10 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.